Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Susanne Hoyer"'
Autor:
Jens Gottlieb, Alexander Reuss, Konstantin Mayer, Karin Weide, Carmen Schade-Brittinger, Susanne Hoyer, Peter Jaksch
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Immunosuppression including high-dose calcineurin inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug monitoring adjusted to target trough levels of CNIs to keep the balance betwe
Externí odkaz:
https://doaj.org/article/c611b720c50549db860596dcdbe3a821
Autor:
Stefanie Howaldt, Andreas Raedler, H-Christian Reinecker, Daniela Berghaus, Susanne Hoyer, Barbara Kaiser, Stefan Schreiber
Publikováno v:
Canadian Journal of Gastroenterology, Vol 7, Iss 2, Pp 241-244 (1993)
Externí odkaz:
https://doaj.org/article/97255cd044384ab4b3c77b9e4915a043
Autor:
Carmen Schade-Brittinger, Alexander Reuss, Karin Weide, Konstantin Mayer, Peter Jaksch, Jens Gottlieb, Susanne Hoyer
Publikováno v:
Trials
Trials, Vol 22, Iss 1, Pp 1-10 (2021)
Trials, Vol 22, Iss 1, Pp 1-10 (2021)
Background Immunosuppression including high-dose calcineurin inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug monitoring adjusted to target trough levels of CNIs to keep the balance between over-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddb166ad650a276f9b9f72a4f5dedcb7
http://europepmc.org/articles/PMC7798016
http://europepmc.org/articles/PMC7798016
Autor:
Jens Gottlieb, Alexander Reuss, Konstantin Mayer, Karin Weide, Carmen Schade-Brittinger, Susanne Hoyer, Peter Jaksch
Background:Immunosuppression including high dose calcineurin-inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug monitoring adjusted to target trough levels of CNIs to keep the balance between over-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34a6ded0700d3a8088748fb19d64e711
https://doi.org/10.21203/rs.3.rs-38454/v1
https://doi.org/10.21203/rs.3.rs-38454/v1
Autor:
Amparo Acker-Palmer, Susanne Hoyer, Stefan Weinges, Joanna Lipka, Max A. Schlager, Inmaculada Segura, Phebe S. Wulf, Jeroen Demmers, Casper C. Hoogenraad, Julia C. Geiger
Publikováno v:
Developmental Cell, 28(4), 381. Cell Press
Developmental Cell, 28(4), 381-393. Cell Press
Dev Cell
Developmental Cell, 28(4), 381-393. Cell Press
Dev Cell
SummaryRegulation of cargo transport via adaptor molecules is essential for neuronal development. However, the role of PDZ scaffolding proteins as adaptors in neuronal cargo trafficking is still poorly understood. Here, we show by genetic deletion in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcece8644aafe5fad97b7d73bc6dd73e
https://doi.org/10.1016/j.devcel.2014.01.018
https://doi.org/10.1016/j.devcel.2014.01.018
Autor:
Andreas Raedler, Stefan Schreiber, Susanne Hoyer, Stefanie Howaldt, Daniela Berghaus, Barbara Kaiser, H-Christian Reinecker
Publikováno v:
Canadian Journal of Gastroenterology, Vol 7, Iss 2, Pp 241-244 (1993)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cd5deeab8e6c6b9c8a18a13cd643fb8
https://doaj.org/article/97255cd044384ab4b3c77b9e4915a043
https://doaj.org/article/97255cd044384ab4b3c77b9e4915a043
Publikováno v:
Multiple Sclerosis and Related Disorders. 3:754
Background/objective Fingolimod, a sphingosine 1-phosphate receptor (S1PR) modulator, is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Following treatment initiation, fingolimod activates S1PR at the surface of cardiac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3f22da70919b5288ed10fe71f9144a4
https://doi.org/10.1016/j.msard.2014.09.189
https://doi.org/10.1016/j.msard.2014.09.189
Publikováno v:
Synthesis. 1986:655-657
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1eed7c4409d4e817e34c0abb026ea20
https://doi.org/10.1055/s-1986-31736
https://doi.org/10.1055/s-1986-31736
Autor:
Volker Limmroth, Judith Haas, Wilhelm Haverkamp, Susanne Hoyer, Olaf Hoffmann, Guillaume Wendt, Christoph Lassek, Michael Lang, Luisa Klotz, Tjalf Ziemssen, Stephan Schmidt, Katrin Schuh, Christian Albert, Heinke Schieb, Ralf Dechend, Stephan Richter, Bert Wagner, Kathrin Gerbershagen, Monika Baier-Ebert
Publikováno v:
BMC Neurology
Background First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose. Individual bradyarrhythmic episodes were evaluated to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f98224ea91ba56596d757ee33dd992e